Table 1.
Two Cohorts and Training and Validation Subcohorts
| Case characteristics | Clinical cohort | Devignot et al[11] cohort | ||
|---|---|---|---|---|
| Entire clinical cohort | PBMC microarray subcohort | PBMC qRT-PCR subcohort | Whole blood microarray subcohort | |
| Training set | Validation set | Validation set | ||
| Suspected dengue cases | 438 | 42 | 22 | 32 |
| Age, y | 8.8 ± 3.3 | 9.0 ± 3.8 | 8.8 ± 3.1 | 7.8 ± 2.5 |
| Sex, % female | 51 | 52 | 60 | 66 |
| Mean day of blood sampling after onset of fever | 3.3 ± 1.5 | 3.1 ± 1.9 | 3.6 ± 1.3 | 5.1 ± 1.0 |
| Confirmed dengue | 316 | 42 | 22 | 32 |
| DENV-1 | 265 | 42 | 10 | 4 |
| DENV-2 | 15 | 0 | 6 | 3 |
| DENV-3 | 0 | 0 | 0 | 16 |
| DENV-4 | 28 | 0 | 6 | 1 |
| Unknown | 8 | 0 | 0 | 8 |
| Secondary infection | 183 | 42 | 22 | 32 |
| Classification according to WHO 2009 criteria | ||||
| Nonsevere dengue, with or without warning signs | 236 | 27 | 15 | 14 |
| Severe dengue | 80 | 15 | 7 | 18 |
Abbreviations: DENV, dengue virus; PBMC, peripheral blood mononuclear cells; qRT-PCR, quantitative real-time polymerase chain reaction; WHO, World Health Organization.